Sareum Holdings PLC
SAR
Company Profile
Business description
Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.
Contact
Langford Arch, London Road
Unit 2a, Pampisford
CambridgeCambridgeshireCB22 3FX
GBRT: +44 1223497700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
5
Stocks News & Analysis
stocks
Major ASX miner reduces aluminium exposure
The Alcoa transaction unlocks value and sharpens ASX miners focus on base metals.
stocks
Vegemite owner’s shares remain expensive on normalising profits.
Australian dairy staple to see profits normalise with shares screening as overvalued.
stocks
Ask the analyst: Where does GYG stand following its US exit?
All roads lead back home for Guzman Y Gomez.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,037.00 | 11.20 | 0.12% |
| CAC 40 | 8,473.64 | 34.43 | -0.40% |
| DAX 40 | 25,795.03 | 15.72 | 0.06% |
| Dow JONES (US) | 52,816.07 | 84.00 | -0.16% |
| FTSE 100 | 10,630.42 | 48.61 | -0.46% |
| HKSE | 23,616.32 | 266.29 | 1.14% |
| NASDAQ | 26,125.54 | 292.87 | 1.13% |
| Nikkei 225 | 69,737.69 | 6.38 | -0.01% |
| NZX 50 Index | 13,763.10 | 144.68 | 1.06% |
| S&P 500 | 7,527.65 | 44.41 | 0.59% |
| S&P/ASX 200 | 8,831.00 | 12.70 | 0.14% |
| SSE Composite Index | 4,041.24 | 2.41 | -0.06% |